insights_auto
Why is DMN down 5,11%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,059 €
arrow_downward
-5,11%(-0,0032) 1D
20-ноя., 20:15:14 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
134,69 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,06 €
High
0,06 €
Low
0,06 €
Mkt. cap
134,69 млн
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
ChartMill
·
1 саат мурун
S&P 500 Most Active Stocks: Netflix and Ford Lead Volume
marketscreener.com
·
1 саат мурун
S&P 500, Dow Enter Correction Territory; Anthropic Tumbles Following Record Debut
GV Wire
·
39 мүнөт мурун
Wall Street Slides on Mounting AI Selloff, S&P 500, Dow Set to Confirm Corrections
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB